Description
Retatrutide Research Peptide
Retatrutide, also identified by the development code LY3437943, is an investigational peptide compound developed for research into coordinated receptor signalling. The molecule is studied as a triple receptor agonist because it interacts with the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR) within a single molecular design .
This Retatrutide research product is supplied as a lyophilized powder in clearly labelled vial formats. Select the required vial content from the available 10 mg, 20 mg or 30 mg options. The stated milligram value represents the total vial content and must not be interpreted as a clinical dose or instruction for use.
What Is Retatrutide (LY3437943)?
Retatrutide is a synthetic peptide studied for its multi-receptor pharmacology. Unlike compounds designed around a single receptor pathway, LY3437943 combines activity at three metabolically relevant receptor systems. This profile has made it a subject of laboratory and clinical research involving receptor pharmacology, incretin signalling and metabolic pathway analysis .
Retatrutide remains an investigational compound. It is not an approved medicinal product and must not be presented as a treatment, cure, weight-loss medicine or substitute for professional medical care .
Triple-Receptor Research Profile
GIP Receptor Activity
The glucose-dependent insulinotropic polypeptide receptor is part of the incretin-signalling system. Retatrutide is studied for its agonist activity at GIPR as one component of its combined receptor profile.
GLP-1 Receptor Activity
GLP-1 receptor signalling is widely investigated in metabolic and incretin research. Retatrutide incorporates GLP-1R agonist activity within the same peptide molecule.
Glucagon Receptor Activity
The third component of the molecule is agonist activity at the glucagon receptor. The coordinated GIPR, GLP-1R and GCGR profile distinguishes Retatrutide from single- and dual-receptor research compounds .
Product Specifications
Specification
Product information
Compound name
Retatrutide
Development code
LY3437943
Compound class
Investigational triple receptor agonist peptide
Research targets
GIPR, GLP-1R and GCGR
Available vial formats
10 mg, 20 mg and 30 mg
Physical form
Lyophilized powder
Product category
Metabolic research peptide
Intended use
Laboratory and scientific research only
Human consumption
Not permitted
Veterinary use
Not permitted
Purity
Add the batch-specific value only when supported by a matching COA
Storage
Follow the batch documentation and institutional laboratory procedures
Research Applications
Within qualified research environments, Retatrutide may be used as a reference compound in projects involving receptor-binding studies, multi-receptor signalling, comparative incretin research, analytical method development and metabolic pathway investigation. Any experimental work should be conducted by trained professionals under applicable institutional, ethical and regulatory standards.
The product listing does not provide a preparation protocol, reconstitution guide, clinical dose or self-administration instructions. Researchers should rely on validated internal procedures and the documentation supplied for the relevant batch.
Quality and Batch Documentation
Product specifications should always correspond to the actual batch being offered. Where available, publish the matching Certificate of Analysis (COA) or independent laboratory report directly on the product page. The document should identify the compound, batch or sample number, analytical method, test date and measured result.
Do not use a certificate belonging to another supplier, concentration or batch. Transparent batch documentation improves product traceability and gives laboratory customers a clearer basis for evaluating the material.
Storage and Handling
Keep the unopened vial under the storage conditions stated in the manufacturer or batch documentation. Protect the material from contamination, moisture, excessive heat and direct light. Handling must be performed by qualified laboratory personnel using appropriate equipment, records and institutional safety procedures.
Research-Use Disclaimer
This product is supplied exclusively for laboratory, analytical and scientific research. It is not intended for human consumption, self-administration, veterinary use, diagnostic use or therapeutic application. Retatrutide remains investigational and has not been approved as a medicine. Information about published studies is provided only to identify the compound and its research context; it is not medical advice, a dosing recommendation or an instruction for use.
What is Retatrutide?
Retatrutide, also known as LY3437943, is an investigational peptide studied for agonist activity at the GIP, GLP-1 and glucagon receptors .
Why is Retatrutide called a triple receptor agonist?
It is described as a triple receptor agonist because one peptide molecule is designed to interact with GIPR, GLP-1R and GCGR. The scientifically accurate term is “triple receptor agonist,” not “GLP-3.”
Is Retatrutide an approved medicine?
No. Retatrutide remains investigational and is not approved as a medicinal product . This listing is strictly for laboratory and scientific research.
What vial formats are available?
This variable product can be configured with 10 mg, 20 mg and 30 mg vial options. Publish only the formats that are genuinely available in your inventory.
Do the vial contents represent clinical doses?
No. The milligram value describes the total amount stated for the vial. It must not be interpreted as a clinical dose, treatment recommendation or self-administration instruction.
Is a Certificate of Analysis available?
Add a downloadable Certificate of Analysis only when it matches the exact product, concentration and batch offered on the page. If no matching document is available, do not claim independent testing or a specific purity percentage.
Is this product intended for human consumption?
No. It is intended exclusively for qualified laboratory and scientific research and is not for human or veterinary use.